Blueprint
— your priorities.
Three minutes of symptom + life-stage check-in. Out comes a ranked plan: top three drivers to focus on, and what to safely ignore for now.
Two working tools, calibrated to female biology — Blueprint synthesizes symptoms into priorities, Supplement Advisor cuts the noise from your stack. Click in. Try it with your own context. Nothing is saved.
"Evely identified my symptom pattern — weirdly accurate — and gave me a clear focus area."
Sarah, 41 · Pilot cohortThree minutes of symptom + life-stage check-in. Out comes a ranked plan: top three drivers to focus on, and what to safely ignore for now.
Drop in what you're already taking. We tell you what's likely working, what's redundant, and what's missing — calibrated to your symptoms and life stage.
These are the production tools — same models, same logic — running in a sandboxed investor environment. We don't want you holding back, so we built it so you can't be held to anything.
You don't sign in. The tools accept input directly without identifying you in any way.
Inputs and outputs are processed in-memory and discarded when you close the tab. Nothing is written to a database.
No logs of what you typed. No replay. Try your own symptoms, your spouse's, a stress-test edge case — none of it reaches us.
This isn't a stripped demo. You're using exactly what cohort members use — minus the personalization that comes from a saved profile.
Across 1,500+ women in our first cohorts, Evely's prioritization layer reliably moved people off generic checklists and onto a focused first move. These are aggregate, anonymized pilot numbers — not projections.
Every priority Evely surfaces is grounded in peer-reviewed research on female endocrinology, sleep, and metabolic health — translated into a model that respects life stage, cycle phase, and individual context.


Two tools live today. Four more are on the path — each one stays inside the same decision-layer thesis: less noise, more direction, calibrated to female biology at every life stage.
If what you saw resonates, we'd love to talk. Founders are taking 30-minute conversations with aligned investors through May.
You're about to open the tool in a sandboxed investor environment.